-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sales in the second quarter increased by 29% , and adjusted EBITDA increased by 42%
The performance of the three growth business units is better than the level before the epidemic in 2019
Raise the target for 2021 : adjusted EBITDA will be between 2.
Sales in the second quarter increased by 29% , and adjusted EBITDA increased by 42%
Sales in the second quarter increased by 29% , and adjusted EBITDA increased by 42%
Sales in the second quarter increased by 29% , and adjusted EBITDA increased by 42%The performance of the three growth business units is better than the level before the epidemic in 2019
The performance of the three growth business units is better than the level before the epidemic in 2019
The performance of the three growth business units is better than the level before the epidemic in 2019Raise the target for 2021 : adjusted EBITDA will be between 2.
Raise the target for 2021 : adjusted EBITDA will be between 2.
Raise the target for 2021 : adjusted EBITDA will be between 2.
Evonik today released its financial report for the second quarter of 2021 .
Evonik Industries chairman library full of music, said: " experience the new crown crisis, Evonik strength has been further enhanced, and have achieved good results in the first half of
Currently, Evonik expects adjusted earnings before interest, taxes, depreciation and amortization ( EBITDA ) to rise to between 2.
2021 In the second quarter, after winning record adjusted EBITDA compared with 2020 , an increase of 42 percent , reaching 6.
In the second quarter of 2021 , Evonik's sales increased by 29% year- on-year to 3.
Although net working capital and taxes are expected to increase, thanks to improved performance, free cash flow in the second quarter increased year-on-year to 101 million euros
Ute Wolf, Chief Financial Officer of Evonik, said: " The cash flow performance in the first half of 2021 was excellent, providing the basis for another 40% cash conversion rate
Business sector performance business sector performance
Specialty Additives Business Unit: Specialty Additives Business Unit: Sales in the second quarter increased by 23% to 922 million euros
Nutrition and Consumer Chemicals Business Unit: Nutrition and Consumer Chemicals Business Unit: Sales in the second quarter increased by 13% to 838 million euros
Smart Materials Business Unit: Smart Materials Business Unit: Sales in the second quarter increased by 35% to 975 million euros
Functional Materials Business Unit: Functional Materials Business Unit: Sales in the second quarter increased by 62% to 708 million euros
